Targeted Protein Degradation (Protacs) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Targeted protein degradation (TPD) using proteolysis-targeting chimeras (PROTACs) and related technologies represents a paradigm-shifting therapeutic approach for neurodegenerative diseases. Unlike traditional small-molecule inhibitors that block protein function, PROTACs recruit the cell's own ubiquitin-proteasome system to selectively destroy disease-causing proteins, including tau], alpha-synuclein, mutant huntingtin, and LRRK2[1]
.
PROTACs are heterobifunctional molecules consisting of three elements: (1) a ligand that binds the target protein (warhead), (2) a ligand that recruits an E3 ubiquitin ligase, and (3) a chemical linker connecting the two. By bringing the target protein into proximity with an E3 ligase, PROTACs trigger polyubiquitination and subsequent proteasomal degradation of the target[2]
.
This approach offers several advantages over conventional therapeutics for neurodegeneration: the ability to eliminate toxic protein species entirely rather than merely inhibiting their activity; catalytic mechanism of action where a single PROTAC molecule can degrade multiple target proteins; and the capacity to target proteins previously considered "undruggable" by traditional pharmacology. As of 2025, the LRRK2 degrader ARV-102 has become the first PROTAC to demonstrate blood-brain barrier penetration and central target engagement in humans, marking a milestone for the field[3]
.
PROTACs hijack the cell's natural protein disposal system. The ubiquitin-proteasome system is the primary pathway for selective protein degradation in eukaryotic cells:
PROTACs exploit step 3 by artificially bringing any target protein into the proximity of an E3 ligase, inducing its ubiquitination and degradation regardless of the target's normal biology[2].
Two E3 ligases dominate current PROTAC design:
Emerging E3 ligase platforms include DCAF15/16, IAPs, and KEAP1, expanding the scope of targetable proteins.
A key advantage of PROTACs is their catalytic mechanism: after inducing degradation of one target molecule, the PROTAC is released and can engage another target. This means sub-stoichiometric concentrations of the PROTAC can achieve near-complete target elimination, potentially reducing dosing requirements and off-target effects compared to occupancy-driven inhibitors[1]
.
LRRK2 (leucine-rich repeat kinase 2) mutations are the most common genetic cause of familial Parkinson's disease, and elevated LRRK2 kinase activity is also implicated in idiopathic PD. While LRRK2 inhibitors reduce kinase activity, PROTAC-mediated degradation eliminates all LRRK2 functions, including scaffolding and protein-protein interaction roles that kinase inhibitors cannot address.
ARV-102 is the most clinically advanced PROTAC for neurodegeneration — an orally bioavailable, brain-penetrant PROTAC targeting LRRK2 for degradation.
Preclinical results:
Phase 1 clinical results (2025):
Development plan: Pending Phase 1 multiple-dose data and IND clearance, Arvinas intends to initiate a Phase 1b trial in patients with progressive supranuclear palsy in the first half of 2026, with potential expansion to Parkinson's Disease.
Tau pathology — including [hyperphosphorylation], aggregation, and prion-like spreading — is the pathological hallmark most closely correlated with cognitive decline in Alzheimer's disease and other tauopathies. PROTACs offer the unique ability to degrade multiple pathological tau species.
Arvinas tau PROTAC program: Preclinical studies have demonstrated that tau-targeting PROTACs can degrade several different forms of tau, including phosphorylated tau species (p-tau181, p-tau217, p-tau231), resulting in reduced insoluble aggregated tau in mouse tauopathy models[5]
.
Dual PROTACs: Researchers have developed dual-targeting PROTACs capable of simultaneously degrading both alpha-synuclein aggregates and total tau. Lead compound T3 achieved degradation efficiency DC50 values of 1.57 μM for alpha-synuclein aggregates and 4.09 μM for total tau, demonstrating the feasibility of multi-target degradation[6]
.
Key advantages over anti-tau antibodies: Unlike tau-targeted therapeutics](/treatments/tau-targeted-therapeutics) based on antibodies (e.g., semorinemab, bepranemab), PROTACs are small molecules that can be administered orally and potentially achieve intracellular target engagement — critical because most pathological tau is intracellular.
alpha-synuclein aggregation into Lewy bodies and Lewy neurites is the pathological hallmark of Parkinson's disease, Lewy body dementia, and multiple system atrophy. alpha-synuclein PROTACs aim to clear both soluble oligomeric and fibrillar forms.
Researchers have developed PROTACs built on pyrrolopyridine-based anchors that selectively bind alpha-synuclein while recruiting cereblon or VHL E3 ligases. Dose-response experiments have demonstrated DC50 values in the low nanomolar range with degradation approaching 80% for lead molecules[6]
.
Mutant huntingtin (mHTT) with expanded polyglutamine repeats forms toxic aggregates in Huntington's disease. PROTACs targeting mHTT offer the potential for selective degradation of the mutant protein while sparing wild-type huntingtin, which retains important cellular functions.
Recent advances:
This selectivity advantage distinguishes PROTACs from antisense oligonucleotide therapies like tominersen, which reduce both mutant and wild-type huntingtin.
TDP-43 Proteinopathy characterizes approximately 97% of ALS and ~50% of FTD cases. PROTACs targeting mislocalized or aggregated TDP-43 are in early preclinical development. Similarly, PROTACs targeting FUS aggregates are being explored for FUS-related ALS/FTD.
Molecular glues are small molecules that stabilize protein-protein interactions between a target protein and an E3 ligase, inducing target degradation. Unlike bifunctional PROTACs, molecular glues are monovalent compounds that create a neo-interface, typically offering:
Thalidomide and its analogs (lenalidomide, pomalidomide) are the prototypical molecular glues, originally discovered through their teratogenic effects but now understood to redirect cereblon E3 ligase activity toward neo-substrates.
LYTACs redirect extracellular and membrane proteins to lysosomes for degradation via the lysosomal pathway, complementing intracellular PROTACs. They consist of a target-binding moiety conjugated to a lysosome-targeting receptor ligand (e.g., mannose-6-phosphate). LYTACs may be particularly useful for degrading extracellular aggregates of amyloid-beta or secreted alpha-synuclein.
AUTACs direct target proteins to [autophagosomes] for degradation, leveraging the autophagic pathway rather than the proteasome. This approach is especially relevant for protein aggregates that are too large for proteasomal degradation — a common situation in neurodegenerative diseases where large fibrils and inclusions accumulate.
AbTACs use bispecific antibodies to recruit membrane-bound E3 ligases (e.g., RNF43) to cell-surface target proteins, inducing their endocytosis and lysosomal degradation. This technology extends TPD to membrane proteins and extracellular targets.
PROTACs are typically larger molecules (700-1000 Da) than conventional small-molecule drugs, making blood-brain barrier (BBB penetration a significant challenge. ARV-102's demonstrated CSF penetration in humans is a critical proof-of-concept for CNS-targeted PROTACs[3]
.
Strategies to improve BBB penetration include:
For proteins with disease-relevant and essential normal functions (e.g., wild-type huntingtin, normal tau, selective degradation of pathological forms while sparing physiological protein is crucial. Approaches include:
At very high concentrations, PROTACs can saturate both the target protein and E3 ligase separately, preventing ternary complex formation — the "hook effect." This creates an inverted U-shaped dose-response curve that must be considered in clinical dosing[2].
Cells may develop resistance to PROTACs through:
Large protein aggregates (fibrils, inclusions) cannot be processed by the 26S proteasome and may require autophagy-based degradation approaches (AUTACs) rather than classical PROTACs. Developing degraders that target both soluble and aggregated forms remains an active area of research.
| Program | Target | Indication | Stage | Company |
|---|---|---|---|---|
| ARV-102 | LRRK2 | PD, PSP | Phase 1 (positive data) | Arvinas |
| Tau PROTAC | tau protein | AD, tauopathies | Preclinical | Arvinas |
| α-Syn PROTAC | alpha-synuclein | PD, DLB, MSA | Preclinical | Multiple |
| mHTT PROTAC | Mutant huntingtin | HD | Preclinical | Multiple |
| Dual PROTAC T3 | Tau + α-Syn | AD, PD | Preclinical | Academic |
The field of targeted protein degradation for neurodegeneration is evolving rapidly:
The study of Targeted Protein Degradation (Protacs) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.